Insider · CIK 0002044677
Reuven Yeganeh
Files at HLSQ (BiomX Inc.), DFNS (T3 Defense Inc.). First filing Mar 13, 2026, latest Mar 18, 2026.
In brief
Reuven Yeganeh files SEC Form 4 as CEO, director and 10% owner at HLSQ (BiomX Inc.), and also at DFNS (T3 Defense Inc.). Since Mar 13, 2026, Reuven Yeganeh has reported 0 open-market buys worth $0 and 2 open-market sells worth $8.3M, the latest filed on Mar 18, 2026.
A track record needs three past buys with six months of prices behind them; Reuven Yeganeh has 0, so none is measured yet.
The newest scored trade: sold $4.9M of HLSQ on Mar 16, 2026, filed Mar 18, 2026, scored 60 (notable). In the last 12 months: 0 buys worth $0 and 2 sells worth $8.3M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
HLSQ: BiomX Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 60Notable | HLSQsell BiomX Inc. | $4.9M 980,000 shares | -218% | - | |
| 60Notable | HLSQsell BiomX Inc. | $3.4M 670,000 shares | -223% | - |
Transactions
Every row this insider has filed, 17 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | HLSQ BiomX Inc. | CConversion Common Stock, $0.0001 par value per shareindirect: Pyu Pyu Capital LLC | +450,000 | $2.00 | $900k | 450,000 | Mar 18, 2026 |
| Mar 16, 2026 | HLSQ BiomX Inc. | SOpen-market sale Common Stock, $0.0001 par value per shareindirect: Pyu Pyu Capital LLC | -450,000 | $5.00 | $2.3M | 0 | Mar 18, 2026 |
| Mar 17, 2026 | HLSQ BiomX Inc. | CConversion Common Stock, $0.0001 par value per shareindirect: Pyu Pyu Capital LLC | +530,000 | $2.00 | $1.1M | 530,000 | Mar 18, 2026 |
| Mar 17, 2026 | HLSQ BiomX Inc. | SOpen-market sale Common Stock, $0.0001 par value per shareindirect: Pyu Pyu Capital LLC | -530,000 | $5.00 | $2.6M | 0 | Mar 18, 2026 |
| Mar 16, 2026 | HLSQ BiomX Inc. | CConversion Series Y Convertible Preferred Stockderivativeindirect: Pyu Pyu Capital LLC | -900 | $0.00 | $0 | 1,060 | Mar 18, 2026 |
| Mar 17, 2026 | HLSQ BiomX Inc. | CConversion Series Y Convertible Preferred Stockderivativeindirect: Pyu Pyu Capital LLC | -1,060 | $0.00 | $0 | 0 | Mar 18, 2026 |
| Mar 16, 2026 | HLSQ BiomX Inc. | SOpen-market sale Common Stock Purchase Warrantsderivativeindirect: Pyu Pyu Capital LLC | -1,300,000 | $5.00 | $6.5M | 2,000,000 | Mar 18, 2026 |
| Mar 16, 2026 | HLSQ BiomX Inc. | SOpen-market sale Common Stock Purchase Warrantsderivativeindirect: Pyu Pyu Capital LLC | -2,000,000 | $5.24 | $10M | 1,700,000 | Mar 18, 2026 |
| Mar 16, 2026 | HLSQ BiomX Inc. | SOpen-market sale Common Stock Purchase Warrantsderivativeindirect: Pyu Pyu Capital LLC | -1,700,000 | $4.76 | $8.1M | 0 | Mar 18, 2026 |
| Mar 11, 2026 | HLSQ BiomX Inc. | CConversion Common Stock, $0.0001 par value per shareindirect: Pyu Pyu Capital LLC | +300,000 | $2.00 | $600k | 30,000 | Mar 13, 2026 |
| Mar 12, 2026 | HLSQ BiomX Inc. | SOpen-market sale Common Stock, $0.0001 par value per shareindirect: Pyu Pyu Capital LLC | -300,000 | $5.00 | $1.5M | 0 | Mar 13, 2026 |
| Mar 13, 2026 | HLSQ BiomX Inc. | CConversion Common Stock, $0.0001 par value per shareindirect: Pyu Pyu Capital LLC | +370,000 | $2.00 | $740k | 370,000 | Mar 13, 2026 |
| Mar 13, 2026 | HLSQ BiomX Inc. | SOpen-market sale Common Stock, $0.0001 par value per shareindirect: Pyu Pyu Capital LLC | -370,000 | $5.00 | $1.9M | 0 | Mar 13, 2026 |
| Mar 12, 2026 | HLSQ BiomX Inc. | CConversion Series Y Convertible Preferred Stockderivativeindirect: Pyu Pyu Capital LLC | -600 | $0.00 | $0 | 2,700 | Mar 13, 2026 |
| Mar 13, 2026 | HLSQ BiomX Inc. | CConversion Series Y Convertible Preferred Stockderivativeindirect: Pyu Pyu Capital LLC | -740 | $0.00 | $0 | 1,960 | Mar 13, 2026 |
| Nov 13, 2025 | DFNS T3 Defense Inc. | AGrant or award Common Stock, $0.0001 par value per share | +10,000 | $0.00 | $0 | 20,000 | Nov 20, 2025 |
| Dec 16, 2024 | DFNS T3 Defense Inc. | AGrant or award Common Stock, $0.0001 par value per share | +10,000 | $1.39 | $14k | 10,000 | Dec 20, 2024 |
Questions about Reuven Yeganeh
Answered from the filings on this page, as of the latest one.
Is Reuven Yeganeh buying or selling?
In the last 12 months Reuven Yeganeh reported 0 open-market buys worth $0 and 2 open-market sells worth $8.3M on SEC Form 4; the latest was sold $4.9M of HLSQ on Mar 16, 2026. Grants, option exercises and tax withholding are not counted.
How did Reuven Yeganeh's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Reuven Yeganeh has 0.
Where does Reuven Yeganeh file Form 4?
Reuven Yeganeh has filed Form 4 at HLSQ (BiomX Inc.); DFNS (T3 Defense Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.